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Abstract
Background: Sphingosine kinase-1 (SphK1) is an oncogenic lipid kinase notably involved in response to anticancer therapies
in prostate cancer. Androgens regulate prostate cancer cell proliferation, and androgen deprivation therapy is the standard
of care in the management of patients with advanced disease. Here, we explored the role of SphK1 in the regulation of
androgen-dependent prostate cancer cell growth and survival.
Methodology/Principal Findings: Short-term androgen removal induced a rapid and transient SphK1 inhibition associated
with a reduced cell growth in vitro and in vivo, an event that was not observed in the hormono-insensitive PC-3 cells.
Supporting the critical role of SphK1 inhibition in the rapid effect of androgen depletion, its overexpression could impair the
cell growth decrease. Similarly, the addition of dihydrotestosterone (DHT) to androgen-deprived LNCaP cells re-established
cell proliferation, through an androgen receptor/PI3K/Akt dependent stimulation of SphK1, and inhibition of SphK1 could
markedly impede the effects of DHT. Conversely, long-term removal of androgen support in LNCaP and C4-2B cells resulted
in a progressive increase in SphK1 expression and activity throughout the progression to androgen-independence state,
which was characterized by the acquisition of a neuroendocrine (NE)-like cell phenotype. Importantly, inhibition of the PI3K/
Akt pathway—by negatively impacting SphK1 activity—could prevent NE differentiation in both cell models, an event that
could be mimicked by SphK1 inhibitors. Fascinatingly, the reversability of the NE phenotype by exposure to normal medium
was linked with a pronounced inhibition of SphK1 activity.
Conclusions/Significance: We report the first evidence that androgen deprivation induces a differential effect on SphK1
activity in hormone-sensitive prostate cancer cell models. These results also suggest that SphK1 activation upon chronic
androgen deprivation may serve as a compensatory mechanism allowing prostate cancer cells to survive in androgen-
depleted environment, giving support to its inhibition as a potential therapeutic strategy to delay/prevent the transition to
androgen-independent prostate cancer.
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Introduction
Prostate cancer is the most frequent malignancy accounting for
25% of all newly diagnosed cancers in men and is the second
leading cause of death from cancer [1]. Primary treatment with
surgery or radiation therapy in patients with organ-confined
prostate cancer demonstrates overall 10-year survival rates of over
75% [2,3]. In spite of that, it is estimated that approximatively
15% of the patients present locally advanced or metastatic disease,
and about 40% of patients will relapse after local therapy [4].
Prostate cancer cell proliferation is regulated by androgens and
androgen deprivation therapy (ADT) is the standard of care in the
management of patients with advanced disease. ADT is initially
effective, reducing both prostate size and prostate-specific antigen
(PSA) levels, but ultimately all patients become resistant to
hormonal manipulation [4]. ADT induces changes in prostate
cancer biology promoting its progression to the androgen-
refractory state or hormone-refractory prostate cancer (HRPC)
phenotype, with an associated life expectancy of only 15 to 20
months. It is not clear how prostate cancer cells make the
transition from androgen-dependent to androgen-independent
status after ADT. Among the multiple mechanisms involved in
circumventing the effects of androgen ablation, the activation of
the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) signaling has
been described as a central pathway [5,6,7,8,9]. Importantly,
clinical studies have confirmed the importance of Akt activation in
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e8048prostate cancer progression to androgen independence and poor
clinical outcome [10,11,12,13,14].
Numerous studies have shown that, after long-term ADT,
prostate cancer cells acquire a neuroendocrine (NE)-like pheno-
type leading to tumor populations enriched in NE cells. NE cells
constitute a minor component of the normal prostate gland and
secrete several neuropeptides that can induce mitogenic effects on
adjacent cancer cells in androgen-depleted conditions [15].
Although NE cells have been described decades ago, their
functional roles in prostate cancer progression have only recently
received considerable attention. Neuroendocrine tumor and serum
biomarkers are up-regulated following ADT in prostate cancer
patients indicative of a poor prognosis [16,17,18,19]. Consistent to
clinical observations, androgen withdrawal-induced NE differen-
tiation is also seen in cell culture and animal models
[20,21,22,23,24], and the transgenic adenocarcinoma of the
mouse prostate model of prostate (TRAMP) cancer shows a
marked increase in prostate neuroendocrine cell population with
disease progression [25].
Sphingosine 1-phosphate (S1P) is a lipid mediator which plays a
major regulatory role in tumor cell growth, survival, invasion, and
angiogenesis [26]. The balance between the cellular levels of S1P
and its metabolic precursors ceramide and sphingosine is regarded
as a switch that could determine whether a cell proliferates or
undergoes apoptosis or growth arrest [27]. A key regulator of this
balance is the sphingosine kinase-1 (SphK1), the enzyme
converting sphingosine into S1P. SphK1 serves the dual function
of producing the pro-growth, anti-apoptotic S1P, and decreasing
intracellular levels of pro-apoptotic ceramide. Further supporting a
role for SphK1 in promoting cancer, SphK1 has been found to act
as an oncogene [28], its mRNA is overexpressed and positive
immunostaining for SphK1 was found in various tumors
[29,30,31,32,33], and the increase in SphK1 expression in tumor
biopsies was correlated with short survival rate in patients with
glioblastoma and breast cancers [30,34]. In addition, SphK1
enzymatic activity and expression are markedly increased in tumor
samples from prostate cancer patients (as compared with normal
counterparts) correlating with other markers such as PSA level,
tumor grade as well as with the clinical outcome after
prostatectomy (Malavaud and Cuvillier, submitted). While SphK1
activity can be stimulated by a wide array of growth factors [26],
we have previously shown in prostate cancer cell and animal
models that anticancer treatments (chemotherapeutic agents or
ionizing radiations) lead to its inhibition suggesting that SphK1
could act a sensor to anticancer therapies [35,36,37,38].
In this study, we explored the potential role of SphK1 in
the regulation of androgen-dependent cell growth and survival in
the hormone-sensitive LNCaP prostate cancer cell model. For the
first time, we show that androgen deprivation exerts a con-
trasting effect on SphK1. While short-term androgen withdrawal
induced a temporary inhibition of SphK1, chronic androgen
depletion triggered an up-regulation of SphK1 correlating
with the NE differentiation of LNCaP and C4-2B cells support-
ing the involvement of SphK1 in the progression toward
androgen-independence.
Results
Short-Term Androgen Deprivation Decreases Cell
Proliferation in LNCaP - but Not in PC-3 Cells - and Is
Associated with Decreased SphK1 Activity
Cell proliferation was markedly reduced overtime in CSS
(androgen-free medium)-treated LNCaP cells when compared to
FBS (which contains low levels of androgens) treated cells (Fig. 1A,
leftpanel). To supportMTTresults, cell counting(Fig. 1A, middle
panel) and [
3H]thymidine incorporation (Fig. 1A, right panel)
measurements confirmed that CSS conditions had a dramatic
effects on cell number and DNA synthesis establishing that MTT
could be used as a surrogate index for cellular proliferation in our
cell model. This was also correlated with the secretion of PSA
whose level was strongly reduced in both CSS-treated cells as
compared to FBS-treated cells (Fig. 1B). On the contrary,
androgen deprivation did not alter the growth of PC-3
hormono-refractory (HR) cells whose growth was only altered
by serum starvation (Fig. 1C).When compared to FBS conditions,
androgen depletion in LNCaP induced a notable decrease in
SphK1 activity within the first 24 h (Fig. 1D, left panel). Later, a
rebound in SphK1 activity was observed, which became
significant beyond 4 days of treatment (Fig. 1D, left panel). In
PC-3 cells, a significant and lasting decrease in SphK1 activity
was only observed under serum deprivation conditions (Fig. 1D,
right panel). mirroring the impact on cell proliferation (Fig. 1C).
As anticipated in PC-3 cells that are unaffected by CSS
conditions, no significant SphK1 changes could be evidenced
(Fig. 1C, D).
The Efficacy of Castration in Orthotopically
Xenotransplanted SCID Mice Is Associated with SphK1
Inhibition
The effect of androgen deprivation was next examined in vivo
using a surgical orthotopic implantation (SOI) of LNCaP and PC-
3 cells overexpressing GFP [36]. Nine and three weeks after SOI
of LNCaP/GFP and PC-3/GFP cells respectively, SCID mice
were randomized into two groups and subjected to castration or
sham treatment. As shown by high-magnification microscopy of a
representative primary LNCaP/GFP tumor, castration induced a
dramatic decrease in tumor volume and mass (Fig. 2A and B)
within 7 days of treatment compared to sham-treated animals.
The efficacy of castration was associated with a significant
decrease in SphK1 activity in tissue extracts (Fig. 2B, right panel).
Additionally, the effect on primary tumor was paralleled by a
marked reduction in metastasis dissemination in the castration-
treated group (Table S1). As expected, castration did not effect
tumor development in SCID mice xenotransplanted with PC-3/
GFP cells (Fig. 2C). Tumor masses and volumes were similar in
both sham-treated and castrated animals (Fig. 2D), and SphK1
activity (Fig. 2D, right panel) as well as metastasis dissemination
(Table S1) were comparable in both groups.
SphK1 Overexpression Renders LNCaP Cells Less
Sensitive to Androgen Depletion
Because an inhibition of SphK1 was observed during short-term
androgen deprivation in vitro (Fig. 1D) and in vivo (Fig. 2B), we
verified whether transfection of LNCaP cells with SphK1 might
render these cells more resistant to androgen depletion. Transfec-
tion efficiency was verified by immunoblotting (Fig. 3A, left panel).
The SphK1 activity of SphK1-overexpressing LNCaP (Fig. 3A,
right panel) was increased to ,1100 pmol/mn/mg protein (i.e.,
,30-fold higher compared to that of empty-vector transfected
cells). The instrumental role of SphK1 inhibition in reduced cell
growth was confirmed by cell viability assays, which showed that
LNCaP overexpressing SphK1 were markedly less sensitive to the
effects of androgen depletion (Fig. 3B). Concomitantly, SphK1
enforced expression was associated with a higher secretion of PSA
in CSS-treated LNCaP cells reflecting its effects on cell
proliferation (Fig. 3C).
SphK1 and Androgen Signaling
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SphK1 Activity in an Androgen Receptor/PI3
Kinase-Dependent Manner
As a down-regulation of SphK1 activity was correlated with the
removal of androgens in LNCaP cells (Fig. 1D), it was of interest to
establishwhetherthiscouldbe reversedbytheadditionofandrogens.
Under CSS conditions, the addition of dihydrotestosterone (DHT)
could trigger an early and transient stimulation of SphK1 (as early as
15 min) after which SphK1 activity returned to basal levels (Fig. 4A).
The rapid stimulation of SphK1 was dependent on activation of the
PI3K/Akt signaling, which has been shown to mediate the rapid
effects of androgens [39,40]. Indeed, while wortmannin (WT)
inhibited both the activation of Akt (Fig. 4B, top) and SphK1
(Fig. 4B, bottom) induced by DHT, the SphK1 inhibitor SKI-2 did
not impact Akt phosphorylation (Fig. 4B, top). The stimulation of the
PI3K/Akt/SphK1 pathway was critical for transmitting the
proliferative effects of DHT under CSS conditions. In fact, similar
to the PI3K inhibitors WT and LY294002 (Fig. 4C), the SphK1
inhibitors SKI-2 and F-12509a could impede DHT-induced cell
proliferation, DNA synthesis as well as PSA secretion (Fig. 4D).
The effect of androgen receptor antagonist was next examined
with bicalutamide. As anticipated, LNCaP cell proliferation
response at 10 nM DHT was totally blunted by 10 mM
bicalutamide (Fig. 5A). The DHT-triggered stimulation of SphK1
activity was also completely inhibited in presence of androgen
receptor antagonist (Fig. 5B).
SphK1 Is Involved in Androgen Depletion-Induced
Neuroendocrine Transdifferentiation of LNCaP and C4-2B
Cells
We next investigated the potential involvement of SphK1 in the
transition to androgen refractory state after chronic androgen
withdrawal. To this end, LNCaP and C4-2B cells, which have
been previously reported to acquire a neuroendocrine (NE)
phenotype [20,21,23,41,42,43] were maintained under CSS
conditions for up to 42 days. LNCaP cells exposed to a
hormone-deficient medium underwent neuroendocrine (NE)
morphological changes (apparent after approximatively 7–10
days) as indicated by soma compaction and development of long
and branched neuritic extensions (Fig. 6A), whereas control
LNCaP parental cells retained a fusiform epithelial morphology
(Fig. 6A). In addition to morphological characteristics, transdiffer-
entiated NE-like prostate cancer cells are defined by the expression
of a number of neurosecretory products including chromogranin A
(CgA) and neuron-specific enolase (NSE). CgA is considered to be
the most reliable indicator of prostatic NE differentiation.
Figure 1. Effect of short-term androgen deprivation on cell growth and SphK1 activity. Overnight serum deprived LNCaP (A, D) and PC-3
(C, D) cells were incubated in presence of 5% FBS, 5% CSS or without serum (SFM) for the indicated times. Cell proliferation in LNCaP (A, left panel)
and PC-3 cells (C) was determined by MTT assay and expressed as percent of control at the beginning of the experiment (Day 0). Cell number (A,
middle panel) and DNA synthesis (A, right panel) were measured as described in Materials and Methods. Columns, mean of at least twenty-four
independent experiments for MTT assay and six experiments for cell counting and DNA synthesis; bars, SD. The P values between the means are as
follow: ***, P,0.001. Secreted PSA level was measured in culture media from LNCaP cells (B). Columns, mean of at least six independent experiments;
bars, SD. The P values between the means are as follow: ***, P,0.001. D, SphK1 activity was determined in both LNCaP and PC-3 cells and expressed
as percent of FBS-treated cells. Columns, mean of at least twelve and six independent experiments for LNCaP and PC-3 cells respectively; bars, SD. The
P values between the means are as follow: ***, P,0.001; **, P,0.01; *, P,0.05; ns, non significant.
doi:10.1371/journal.pone.0008048.g001
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showed that CgA expression was very low in both parental LNCaP
(Fig. 6A, lower panel) and C4-2B (Figure S1) cells, while its
expression level was greatly enhanced over time in hormone-
deficient medium. Furthermore, compared to non hormone-
deprived LNCaP cells (D0), a 3-fold increase in NSE secretion to
the medium was found after 42 days under CSS conditions
indicative of a NE-like phenotype (Fig. 6A, right panel). Based on
our previous observations that SphK1 activity upon androgen
deprivation was only transiently inhibited with a significant
rebound within 4 days of incubation in CSS medium (Fig. 1D),
we then analyzed the SphK1 activity up to 42 days during the NE
transdifferentiation process. Remarkably, SphK1 activity (Fig. 6B)
increased progressively up to a 4-fold increase after 42 days of
androgen depletion. This was further illustrated by a marked
increase in S1P content (Fig. 6B, inset). In parallel, SphK1 protein
expression was significantly increased (Fig. 6B, right panel). The
activation of SphK1 was correlated with stimulation of Akt
(Fig. 6B, right panel), a pro-survival signaling pathway reported to
be up-regulated during NE transdifferentiation of LNCaP induced
by androgen depletion [6,7,23,45]. Comparable findings were
observed in the C4-2B cell model (Figure S1).
In line with previous studies [6], pharmacological inhibition of
the PI3K/Akt pathway could impede NE transdifferentiation of
both LNCaP (Fig. 6C) and C4-2B (Figure S1) maintained for 10
days under CSS conditions. Of note, the blockade of CgA
accumulation induced by the PI3K inhibitors WT and LY294002
was markedly associated with a decrease in both Akt phosphor-
ylation and SphK1 activity (Fig. 6C, right panel and Figure S1).
To investigate the functional role of SphK1 in NE transdiffer-
entiation, we examined the effect of the pharmacological inhibitor
SKI-2 on LNCaP and C4-2B cells. In presence of SKI-2 (5 mM),
Figure 2. Effect of castration on tumor growth and SphK1 activity of established GFP-expressing human LNCaP and PC-3 cells in
SCID mice. Nine and three weeks after SOI of LNCaP/GFP and PC-3/GFP cells respectively, SCID mice were randomized into two groups. These
animals were then subjected to castration or sham treatment. Representative fluorescent primary LNCaP (A) and PC-3 (C) tumors from sham- and
castration-treated animals at the time of autopsy (7 days post-treatment). Tumor mass of excised primary LNCaP (B, left panel) and PC-3 (D, left
panel) GFP-labeled tumor. Columns, means from 8 animals; bars, SE. SphK1 activity was measured in tissue extracts obtained from sham-, and
castration-treated LNCaP (B, right panel) and PC-3 (D, right panel) tumor bearing animals. Columns, means from 8 animals; bars, SE. The two-tailed P
values between the means are as follow: ***, P,0.001; or ns, not significant.
doi:10.1371/journal.pone.0008048.g002
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with LNCaP exhibiting a rounded morphology with short rarely
branched cellular processes (not shown). Moreover, both secretion
of NSE (Fig. 6D, left panel) and CgA accumulation (Fig. 6D, right
panel and Figure S1) were markedly diminished while Akt
phosphorylation was unchanged hence suggesting that SphK1
inhibition can to a certain extent block the NE transdifferentiation.
Physiological or pharmacological agents that increase intracel-
lular levels of cyclic AMP (cAMP) can induce the development of a
NE morphology in LNCaP or C4-2 cells in presence of steroids
[41,44,46]. Of note, cAMP increase has been previously reported
to be associated with activation of SphK1 in osteoblasts [47].
Hence, we examined the role of cAMP as a potential upstream
regulator of SphK1 during NED. LNCaP and C4-2B cells were
stimulated with the adenylate cyclase activator forskolin (Fsk) and
the phosphodiesterase inhibitor IBMX, or with epinephrine (Epi),
a b-adrenergic receptor agonist. The treatment with Fsk/IBMX or
Epi strongly stimulated SphK1 activity (Fig. 7A), and correlated
with increased cAMP content (Fig. 7B) and acquisition of NE
morphology (data not shown) characterized biochemically by CgA
accumulation (Fig. 7C). Interestingly, the pharmacoligical inhibi-
tion of SphK1 did not have any effect on cAMP levels (Fig. 7B)
whereas it did markedly inhibit NED (Fig. 7C). Remarkably,
under androgen deprivation conditions, a similar increase in
cAMP intracellular levels was observed, which could not be
blocked by pharmacological inhibition of SphK1 (Fig. 7D). These
results evoke a role for cAMP for the stimulation of SphK1 activity
during NED.
In order to determine whether the in vitro findings of the
potential involvement of SphK1 in NE differentiation had any
relevance to human disease, sections from a representative patient
who underwent palliative transurethral resection for local
recurrence under complete androgen blockade were immuno-
stained for CgA and SphK1 expression (Fig. 8). SphK1 staining
was restricted to cytoplasm with some cells being more intensely
stained than the others (Fig. 8B, open arrowhead). Fibromuscular
stroma did not stain positive for SphK1. CgA staining was
observed in a minority of cancer cells, approximately 10%, in the
form of secretory granuli (H, Fig. 8D). Co-expression of CgA in
blue with brown SphK1 resulted in intense dark brown signal
(solid arrowhead). Note in Fig. 8A (bottom) and Fig. 8C, the
neuron-like appearance of the double-labeled cancer cell (solid
arrow).
The transition to the androgen refractory state during chronic
androgen depletion is characterized in vitro by a loss of response of
androgen-deprived cells to either FBS or DHT [20]. As early as 7
days and by 14 days of androgen withdrawal, LNCaP were totally
unresponsive after transfer to FBS conditions or when treated with
Figure 3. SphK1 overexpression renders LNCaP cells more resistant to short-term androgen deprivation. SphK1 expression in LNCaP
cells was analyzed by Western blotting using anti-FLAG antibody (A, left panel). Resting SphK1 activity was measured in LNCaP/neo and LNCaP/
SphK1 cells (A, right panel). B, overnight serum deprived LNCaP cells were incubated in presence of 5% FBS or 5% CSS for 6 days. Cell proliferation
was then determined and expressed as percent of 5% FBS-treated cells. Columns, mean of at least twelve independent experiments; bars, SD. The P
values between the means are as follow: ***, P,0.001. C, secreted PSA level was measured in culture media from LNCaP/Neo and LNCaP/SphK1 cells
after 24 h of incubation in 5% CSS medium. Columns, mean of at least six independent experiments; bars, SD. The P values between the means are as
follow: ***, P,0.001.
doi:10.1371/journal.pone.0008048.g003
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PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e8048Figure 4. DHT stimulates SphK1 activity in a PI3 kinase-dependent manner in LNCaP cells. A, overnight serum deprived LNCaP cells were
incubated under 5% CSS conditions and treated with 10 nM DHT for the indicated times. SphK1 activity was quantified and expressed as percent of
untreated cells. Columns, mean of at least six independent experiments; bars, SD. The P values between the means are as follow: ***, P,0.001;
**, P,0.01; ns, non significant. B, overnight serum deprived LNCaP cells were incubated with 10 nM DHT for 45 min in presence or not of 2.5 mM SKI-
2 or 200 nM wortmannin (WT). Cell lysates were assayed for phospho-Akt and Akt expression by Western blot analysis. Similar results were obtained
in three independent experiments (top). Overnight serum deprived LNCaP cells were incubated under 5% CSS conditions and treated with or without
10 nM DHT and 200 nM wortmannin (WT) for 45 min, and essayed for SphK1 activity (bottom). Columns, mean of at least five independent
experiments; bars, SD. The P values between the means are as follow: **, P,0.01; ns, non significant. C, overnight serum deprived LNCaP cells were
incubated in FBS or in CSS conditions for 6 days with or without 200 nM wortmannin (WT) or 1 mM LY294002 in presence or not of 10 nM DHT as
indicated. Cell proliferation was determined by MTT assay and expressed as percent of control at the beginning of the experiment (Day 0). Columns,
mean of at least eight independent experiments; bars, SD. The P values between the means are as follow: ***, P,0.001; ns, non significant. D,
overnight serum deprived LNCaP cells were incubated in FBS or in CSS conditions with or without 2.5 mM of SKI-2 or F-12509a in presence or not of
10 nM DHT for 24 h (top), 48 h (middle) or 6 days (bottom). Secreted PSA level was quantified 24 h after the indicated treatment (top). DNA
synthesis and MTT-based cell proliferation measurement were expressed as percent of control at the beginning of treatment, 2 and 6 days,
respectively. Columns, mean of at least five independent experiments; bars, SD. The P values between the means are as follow: ***, P,0.001;
**, P,0.01; or ns, non significant.
doi:10.1371/journal.pone.0008048.g004
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secretion of PSA (Fig. 9A, right panel). However, the NE-like
phenotype is reversible upon replenishing the media with complete
serum during several weeks [20]. When LNCaP androgen-
depleted for 42 days were switched back to normal FBS medium,
cell growth resumed over the period of the following week and,
within the next 21 days in FBS medium, the cell morphology
reverted to that of parental LNCaP cells (data not shown). As
demonstrated in Fig. 8B, these cells were now not only able to
grow normally and secrete PSA in presence of FBS like parental
LNCaP (Fig. 1A), but also to respond again to the addition of
DHT under CSS conditions similar to parental cells (Fig. 4C and
D). Interestingly, the reversability induced by replenishing the
media with complete serum for 21 days was associated with a
profound down-regulation of SphK1 activity (Fig. 9C), which went
back to the levels found in parental cells. These data suggest that
SphK1 could represent an adaptable mechanism by which NE
like-cells might survive in an environment deprived from
androgens.
Discussion
Compelling evidence has implicated SphK1 in promoting
oncogenesis and response to anticancer therapies. On the one
hand, SphK1 expression is up-regulated at the message or protein
level in various solid tumors [29,30,31,32,33], and has been linked
with poor survival for brain and breast cancers [30,34]. On the
other hand, anticancer treatments (chemotherapies, radiation
therapy) trigger down-regulation of SphK1 activity in various
cancer cell and animal models suggesting that SphK1 could act as
a ‘‘sensor’’ to anticancer therapies particularly in prostate cancer
[36,37].
Here, we explored the potential role of SphK1 in the androgen-
controlled cell growth and survival of the hormone-sensitive
LNCaP prostate cancer cell model. As formerly established,
androgen deprivation reduced cell growth and PSA secretion of
LNCaP cells. Simultaneously, SphK1 activity was significantly
down-regulated. The observed SphK1 inhibition was not relying
on de novo synthesis of ceramide (data not shown), which has been
previously reported to accumulate following androgen ablation in
LNCaP cells [48]. Moreover, neither oxidative stress nor
cathepsins - which have been previously implicated in SphK1
activity inhibition caused by other stimuli in various cell systems
[49,50] - seemed to be involved (data not shown). The short-term
efficacy of androgen depletion was confirmed in vivo using an
orthotopic model of xenotransplanted LNCaP cells where
castration could not only noticeably reduce tumor size and
metastasis dissemination but also induce a significant SphK1
inhibition. Of note, in hormono-insensitive PC-3 cells, neither
androgen deprivation in vitro nor castration in vivo had any effect on
tumor growth and SphK1 activity. SphK1 overexpression
markedly inhibited the antiproliferative effect resulting from
androgen removal. These results emphasize other findings
establishing that enforced expression of SphK1 displays a
cytoprotective effect against various stimuli such as chemothera-
peutics notably in prostate cancer cells [36].
On the other hand, restoring the androgen environment was
associated with a surge in SphK1 activity. The addition of
dihydrotestosterone (DHT) induced a rapid and ephemeral
activation of SphK1 suggestive of a non-genomic effect. The
PI3K/Akt cascade has also been reported to participate in the
rapid effects of DHT through a direct interaction between a
membrane associated androgen receptor and PI3K [39,40].
Herein, we demonstrate that SphK1 stimulation occurs down-
Figure 5. Bicalutamide inhibits cell proliferation and SphK1
stimulation triggered by DHT. Overnight serum deprived LNCaP
cells were incubated under 5% CSS conditions and treated with or
without 10 mM bicalutamide in presence or not of 10 nM DHT for 2 (A,
top)o r6 d a y s( A, bottom). DNA synthesis and cell counting
measurements were expressed as percent of control at the beginning
of treatment. B, overnight serum deprived LNCaP cells were incubated
with 10 nM DHT for 30 min in presence or not of 10 mM bicalutamide,
and SphK1 activity was quantified and expressed as percent of control
at the beginning of treatment. Columns, mean of at least five
independent experiments; bars, SD. The P values between the means
are as follow: ***, P,0.001; **, P,0.01; or ns, non significant.
doi:10.1371/journal.pone.0008048.g005
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inhibitor, wortmannin could totally abrogate SphK1 stimulation
upon DHT addition while SphK1 inhibition had no effect on
DHT-induced phosphorylation of Akt. Further supporting the
instrumental role played by SphK1 in the adaptation to hormonal
environment, the pharmacological SphK1 inhibitors could
potently (although not completely) inhibit the increase in cell
proliferation and PSA secretion triggered by DHT.
Differential mechanisms are observed between short- and long-
term androgen deprivation. It is well established both in cell culture
and from clinical studies that the transition to the hormone-
refractory state is correlated by the acquisition of a neuro-endocrine
(NE) like phenotype [16,17,18,19,20,21,22,23,24], in which the
activation of the PI3K/Akt signaling has been implicated
[5,6,7,8,9,10,11,12,13,14].
A major finding of our study is the spectacular increase in
SphK1 activity, which appears to be dependent on cyclic AMP
production, during the NE-differentiation process. It is tempting to
speculate that the SphK1 activation upon chronic androgen
deprivation may serve as an adaptive mechanism allowing prostate
cancer cells to survive in androgen-depleted environment, as
SphK1 is a well described pro-survival pathway via the effects of
sphingosine 1-phosphate [27]. Consistent with an hypothesis of an
adaptive functionality for SphK1, replenishing the media with
complete serum was associated with the reversal of SphK1 activity
towards its basal levels. In addition, pharmacological inhibition of
SphK1 during chronic androgen depletion was capable of
reversing at least partially the NE differentiation process. Further
supporting this uncovered role for SphK1 during the transition to
the hormone-refractory state, immunohistochemical studies of
prostate cancer human samples showed for the first time that CgA
positive-NE cells co-expressed SphK1. As NE cells secrete several
neuropeptides with mitogenic effects on adjacent cancer cells in
androgen-depleted conditions [15], it would be interesting to
determine whether NE cells might represent a source of
sphingosine 1-phosphate, which then could act in a paracrine
Figure 6. The progression of LNCaP to androgen-refractory state is associated with increase in SphK1 expression and activity. A,
representative phase-contrast images of LNCaP cells at the beginning of the experiment (Day 0) and after 42 days of incubation in charcoal stripped
conditions (Day 42). Chromogranin A (CgA) content was evaluated by immunoblotting at the indicated times (bottom).Secreted Neuron Specific
Enolase (NSE) level was measured in culture media from LNCaP cells at the indicated times (right panel). Columns, mean of five independent
experiments; bars, SD. The two-tailed P values between the means are as follow: ***, P,0.001. SphK1 activity (B, left panel) was determined at the
indicated times in LNCaP cells incubated in CSS conditions. Points, mean of five independent experiments; bars, SD. The P values between the means
are as follow: ***, P,0.001. Inset, S1P content as shown by TLC. Right panel, expression of SphK1, phospho-Akt, and Akt were analyzed by Western
blotting at the indicated times. Similar results were obtained in five independent experiments. C, expression of CgA and phospho-Akt (left panel) and
SphK1 activity (right panel) were analyzed 10 days after treatment or not with 1 mM LY294002 or 200 nM wortmannin (WT) under charcoal stripped
conditions. Columns, mean of five independent experiments; bars, SD. The two-tailed P values between the means are as follow: ***, P,0.001. D,
secreted NSE level was measured in culture media 10 days after treatment or not with 5 mM SKI-2 under charcoal stripped conditions (left panel).
Expression of CgA and phospho-Akt were analyzed by western blot (right panel). Columns, mean of five independent experiments; bars, SD. The two-
tailed P values between the means are as follow: **, P,0.01.
doi:10.1371/journal.pone.0008048.g006
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e8048Figure 7. The increase in SphK1 activity during NED is cyclic AMP- dependent. A, SphK1 activity was determined in LNCaP and C4-2B cells
treated for 3 days in absence or in presence of 10 mM Fsk/10 mM IBMX or 10 mM Epi. B, intracellular concentrations of cAMP were quantified in
LNCaP and C4-2B cells treated for 3 days with 5% FBS or 10 mM Fsk/10 mM IBMX in absence or in presence of 5 mM SKI-2. C, chromogranin A (CgA)
content was evalated by immunoblotting in LNCaP and C4-2B cell extracts incubated for 3 days with or without 5 mM SKI-2 in presence of 5% FBS,
10 mM Fsk/10 mM IBMX or 10 mM Epi. Similar results were obtained in three independent experiments. D, intracellular concentrations of cAMP were
quantified in LNCaP and C4-2B cells before or 14 days after treatment or not with 5 mM SKI-2 under charcoal stripped conditions. Columns, mean of
three independent experiments; bars, SD. The two-tailed P values between the means are as follow: ***, P,0.001; *, P,0.05; or ns, non significant.
doi:10.1371/journal.pone.0008048.g007
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angiogenesis [26].
Although effective, taxane-based chemotherapy for HRPC can
delay the fatal outcome by only a few weeks or months,
emphasizing the urgent need for new concepts to tackle the
hormone-refractory state. By virtue of the uncovered role of
SphK1 in mediating the transition from androgen-dependent to
androgen refractory state, the pharmacological inhibition of
SphK1 and its downstream signaling could represent a viable
strategy to prevent or delay the progression to hormone-refractory
prostate cancer.
Materials and Methods
Ethics Statement
All animal experiments were conducted as per the guidelines of
the European Council Directive 86/609/EEC and approved by
the local Inserm Animal Care and Use Committee.
Cell Lines and Culture Conditions
Human prostate cancer hormone-sensitive LNCaP (DSMZ,
Braunschweig, Germany) and C4-2B (Viromed, Minnetonka,
MN), and hormone-insensitive PC-3 cells were cultured in RPMI
1640 containing 5% fetal bovine serum (FBS) and passaged less
than 15–20 times. FLAG-tagged wild-type human SphK1 cDNA
[51] was used for stable transfection of LNCaP cells. Mass pools of
stable transfectants were selected in growth medium with 0.8 mg/
ml G418. Empty vector and wild-type SphK1-transfected cells
were designated LNCaP/Neo and LNCaP/SphK1, respectively.
Stably transfected green fluorescent protein (GFP)-tagged LNCaP
and PC-3 cells used for in vivo experiments were maintained in
medium containing 0.5 mg/ml G418.
For optimal attachment, cells were plated and cultured for 48 h.
Thereafter, the medium was replaced by serum-free and phenol
red-free medium overnight before the indicated treatments.
Materials
Culture medium, serum, and antibiotics were from Invitrogen
(Cergy-Pontoise, France). Charcoal-stripped serum (CSS) was
from Hyclone (Perbio Science, Brebie `res, France). Poly-D-Lysine
was from BD Biosciences (Le Pont-De-Claix, France). Dihydro-
testosterone (DHT), bicalutamide, forskolin (Fsk), isobutylmethyl-
xanthine (IBMX), epinephrine (Epi) were from Sigma. The
sesquiterpene quinone F-12509a [52,53] was a gift from Dr
Kohama (Daiichi-Sankyo Ltd., Tokyo, Japan). SKI-2 sphingosine
kinase inhibitor [29,36] and the PI3Kinase inhibitors, wortmannin
and LY294002 were from Calbiochem (Fontenay-sous-Bois,
France). [c-
32P]-ATP (3,000 mCi/mmol) was purchased from
Perkin-Elmer (Courtaboeuf, France), and silica gel 60 high-
performance TLC plates were from VWR (Fontenay-sous-Bois,
France).
Cell Viability Assay
Cell viability was carried out using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) dye reduc-
tion assay [54]. Cells were seeded in poly-D-Lysine coated tissue
culture plates (6-well) at a density of 36,000 and 14,000 cells/well
for LNCaP and PC-3 cells respectively. At the end of the
experiments, LNCaP and PC-3 cells were incubated with MTT
reagent for 1 and 3 h, respectively.
Cell Counting
At the indicated times, cells were harvested by trypsinization and
resuspended in culture medium. Aliquots were diluted 50-fold in
Figure 8. Co-expression of SphK1 and CgA in prostate cancer
human samples. Dual immunostaining with anti-SphK1 (brown) and
anti-CgA (blue) of a resection specimen harvested in a 84 y.o man with
T4NxM1 prostate cancer under complete androgen blockade. Low
serum PSA and positive serum NSE suggested poorly differentiated
cancer with neuroendocrine features, as confirmed by pathological
examination of the resected sample showing high grade prostate
cancer (Gleason 9) with positive staining for CgA. Blue granular
secretion characteristic of neuroendocrine differentiation is colocalized
with brown SphK1 immune reactivity in neuron-like cells (solid
arrowhead).
doi:10.1371/journal.pone.0008048.g008
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counted in a model Z1 Coulter particle counter and averaged.
Measurement of DNA Synthesis
At the indicated times, cultures were pulsed with 1 mCi of [
3H]-
thymidine for 6 h and radioactivity incorporated into trichlor-
oacetic acid-insoluble material measured as previously described
[55].
Western Blot Analysis and Antibodies
Western blotting was performed as previously described [54].
Rabbit anti-SphK1 (gift from Dr Pitson, IMVS, Adelaide,
Australia), rabbit anti-Akt (Cell Signaling Technology # 9272),
rabbit anti-Akt/phospho Ser473 (Cell Signaling Technology #
9271), mouse anti-CgA (Ventana Medical Systems), and mouse
anti-FLAG (Sigma, clone M2) were used as primary antibodies.
Proteins were visualized by ECL detection system (Perbio Science)
using anti-rabbit or anti-mouse HRP-conjugated IgG (Bio-Rad,
Marnes La Coquette, France). Equal loading was confirmed by
probing the blots with the mouse anti-b-actin (Sigma, clone AC40)
or anti-tubulin (Sigma, clone DM1A).
Sphingosine Kinase-1 Assay
SphK1 activity was quantified as described previously [52], and
determined in the presence of 50 mM sphingosine, 0.25% Triton
X-100 and [c-32P]-ATP (10 mCi, 1 mM) containing 10 mM
MgCl2. The labelled S1P was separated by thin layer chromatog-
raphy on silica gel 60 with 1-butanol/ethanol/acetic acid/water
(80:20:10:10, v/v) and visualized by autoradiography. Activity was
expressed as picomoles of S1P formed/min/mg of protein.
Quantitation of Secreted PSA and NSE Levels
Cells were seeded at an initial density of 7,800 and 4,200 cells/
cm
2 for LNCaP and PC-3 respectively. After treatment, culture
media were collected and centrifuged. Total PSA was quantified
by the Abbott MEIA PSA assay (Abbott AxSYM systemH PSA
total). NSE levels were determined by the TRACE (Time
Resolved Amplified Cryptate Emission) technology, based on a
non-radiative transfer of energy (Brahms NSE KryptorH).
cAMP Assay
The intracellular concentration of cAMP was carried out with
the cAMP complete enzyme immunoassay kit from Assay designs
Figure 9. The reversability of the neuroendocrine-like phenotype by exposure to normal medium is associated with down-
regulation of SphK1 activity. A, LNCaP cells were left under CSS conditions for the indicated times (from 0 to 42 days). Cells were then collected
and plated in CSS for 2 days to ensure complete adhesion before treatment with 5% FBS, 5% CSS with or without 10 nM DHT for 6 days (left panel)
or 24 h (right panel). Cell proliferation was expressed as percent of control at the beginning of the 6 days treatment (A, left panel). Secreted PSA
level was quantified 24 h after treatment with 5% FBS, 5% CSS with or without 10 nM DHT of LNCaP cells (A, right panel). Columns, mean of five
independent experiments; bars, SD. The P values between the means are as follow: ***, P,0.001; or ns, not significant. B, LNCaP cells were left in CSS
conditions for 42 days and then cultured back for an additional 21 days in 5% FBS. Cells were then collected and plated in 5% FBS conditions for 2
days to ensure complete adhesion before treatment with 5% FBS, 5% CSS with or without 10 nM DHT for 6 days (left panel)o r2 4h( right panel). Cell
proliferation was expressed as percent of control at the beginning of the 6 days treatment (B, left panel). Secreted PSA level was quantified 24 h after
treatment with 5% FBS, 5% CSS with or without 10 nM DHT of LNCaP cells (B, right panel). Columns, mean of five independent experiments; bars, SD.
The P values between the means are as follow: ***, P,0.001; **, P,0.01; or ns, not significant. C, LNCaP cells were cultured under CSS conditions for
42 days and then cultures for 21 days in 5% FBS or 5% CSS as indicated, then SphK1 activity was assessed. Columns, mean of five independent
experiments; bars, SD. The two-tailed P values between the means are as follow: ***, P,0.001.
doi:10.1371/journal.pone.0008048.g009
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manufacturer.
Animals
6-week-old male SCID mice were obtained from Charles River
(Saint Germain sur l’Arbresle, France).
Surgical Orthotopic Implantation and Castration
Intraprostatic prostate cancer xenografts were established in
SCID mice by surgical orthotopic implantation [36]. Mice were
anesthetized by isoflurane inhalation and placed in the supine
position. A lower midline abdominal incision was made and 20 mL
tumor cell suspension (1610
6 cells) was injected into the dorsal lobe
ofthe prostate.The incision was closed intwo layerswith 4/0Dexon
interrupted sutures. All procedures were done with a dissecting
microscope. After anesthesia by isoflurane inhalation, testes were
gently pushed into the scrotum and a 5 mm incision was made
under. Each testis was surgically removed, and the spermatic cord
and vascular plexus were tied with sterile suture to prevent
hemorrhage. In sham controls, scrotal incision alone was performed.
Autopsy, Histology and In Vivo Fluorescence Imaging
One week after castration, all mice were anesthetized and
euthanized by cervical dislocation for direct internal imaging. A
long midline incision was made to access the abdominal and the
thoracic cavities. The fluorescent primary tumor was removed en
bloc with the seminal vesicles and a meticulous fluorescence-assisted
exploration was conducted to establish the presence of periaortic
nodal extension, as well as adrenal, liver, and lung metastasis. GFP
fluorescence was detected with a Leica MZFL III fluorescence
stereomicroscope (Leica Microsystems, Wetzlar, Germany). High-
resolution 16-bit images (1.39261.040 pixels) were captured by a
thermoelectrically cooled charge-coupled device camera (Cool-
SNAP HQ, Roper Scientific, Evry, France). To visualize the whole
tumor and lymph nodes or micrometastases, 68a n d 635
magnifications were used, respectively. Selective excitation was
produced with a Mercury Arc Lamp (HBO, Osram, Munich,
Germany) and a GFP filter (Leica). Color images were obtained
using a Micro*color tunable RGB filter (CRI, Woburn, MA). The
images were processed for contrast and brightness and the
fluorescence was analysed with MetaVue 6.2 software (Princeton
Instruments, Trenton, NJ). The fluorescent area of the tumors was
defined as a region of interest (ROI). A manual definition was used
to distinguish between the fluorescent tumor area from other dark
tissues. The area (a) of a ROI and the small diameter (d) were used
to assess tumor volume (v) using the formula v=a6d62/3.
Immunohistochemistry
Sections were incubated for 4 hrs with primary rabbit anti-SphK1
antibody (1:200) and revealed by the EnVision+ peroxidase kit and
diaminobenzidine (DAB) chromogen substrate (Dako, Glostrup,
Denmark). In the second reaction, sections were incubated with
primary anti-Chromogranin A (clone LK2H10, Ventana Medical
Systems, Tucson, AZ) in a dedicated staining system (Ventana) and
revealed with anti-mouse immunoglobulins and alkaline phospha-
tase-conjugated streptavidin. Alkaline phosphatase activity was then
revealed with Fast Blue (BB salt; 10 mg/10 ml TBS 0.1M, pH 8.2).
Statistical Analysis
The statistical significance of differences between the means was
evaluated using the unpaired Student’s t test or the one-way
analysis of variance (ANOVA) test. The frequencies of metastasis
between the two groups were compared using Fisher’s exact test.
All statistical tests were two-sided and the level of significance was
set at P,0.05. Calculations were performed using Instat
(Graphpad Software, San Diego, CA).
Supporting Information
Figure S1 The progression of C4-2B to androgen-refractory
state is associated with increase in SphK1 expression and activity.
A, Chromogranin A (CgA) content was evaluated by immuno-
blotting at the indicated times. B, SphK1 activity (left panel) was
determined at the indicated times in C4-2B cells incubated in CSS
conditions. Points, mean of five independent experiments; bars,
SD. The P values between the means are as follow: ***, P,0.001.
Expression of SphK1, phospho-Akt, and Akt were analyzed by
Western blotting at the indicated times. (right panel). Similar
results were obtained in five independent experiments. C,
expression of CgA and phospho-Akt (left panel) and SphK1
activity (right panel) were analyzed 10 days after treatment or not
with 1 mM LY294002 or 200 nM wortmannin (WT) under
charcoal stripped conditions. Columns, mean of five independent
experiments; bars, SD. The two-tailed P values between the means
are as follow: ***, P,0.001. D, Expression of CgA and phospho-
Akt were analyzed by western blot. Columns, mean of five
independent experiments; bars, SD. The two-tailed P values
between the means are as follow: **, P,0.01.
Found at: doi:10.1371/journal.pone.0008048.s001 (0.38 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0008048.s002 (0.05 MB
DOC)
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